A piece of news
Around the world pancreatic cancer affects 100,000 people, while colon cancer affects over 1,500,000. This represents a burden for healthcare systems of over 45 billion dollars
Endor Nanotechnologies, a company that specializes in developing innovative cancer treatments based at the Barcelona Science Park, will start Phase II of clinical trials on an innovative treatment for pancreatic and colon cancer capable of overcoming tumor resistance.
The treatment has had extraordinary levels of success in animal models of pancreatic and colon cancer. It is currently ready for the clinical trial phase with patients, to study how well this new approach to cancer treatment works.
Endor's cancer treatment was awarded the 'Best Biotechnology Product Award 2016' at the European Biotechnology Congress, organized by the European Biotechnology Thematic Network Association (EBTNA).
"This radical new treatment is innovative in that it acts on the biological attributes of tumor cells, which mutate from one generation to the next, resulting in drug resistance. The treatment works on the way the tumor grows independently of the cells' biochemical composition, which means the tumor is not able to generate resistance. This suggests higher levels of efficiency than ever before", explained Joaquín Querol, Endor founder and CEO.
If the results of the study are confirmed, Endor has already begun talks with major pharmaceutical companies to ensure that the treatment is available as soon as possible.
Currently, over 100,000 people around the world are affected by pancreatic cancer. Life expectancy is less than five and a half months, and it is the only type of cancer that is expected to see an increase in the number of deaths over the next five years, according to the organization Pancreatic Cancer Europe. There are currently over 1,500,000 colon cancer patients. Both cancers are a burden on healthcare systems worth around 45 billion dollars, according to the latest report from Business Insights.